Merck Acquires Terns for $6.7 Billion, Securing 'Unprecedented' Leukemia Treatment Amid Keytruda Expiration Concerns

Merck Acquires Terns for $6.7 Billion, Securing ‘Unprecedented’ Leukemia Treatment Amid Keytruda Expiration Concerns